8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported) June 13, 2006



                          MEDISCIENCE TECHNOLOGY CORP.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


        NEW JERSEY                      0-7405                   22-1937826
- --------------------------------------------------------------------------------
(State or other jurisdiction          (Commission              (IRS Employer
       of incorporation)              File Number)           Identification No.)


1235 Folkestone Way, P.O. Box 598, Cherry Hill, New Jersey            08034
- --------------------------------------------------------------------------------
        (Address of principal executive offices)                    (Zip Code)

       Registrant's telephone number, including area code (215) 485 0362

         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2- below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17CFR240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13 e-4(c) under the
    Exchange Act (17 CFR 240.13 e-4(c))





Section 1   Registrants Business and Operations

Item 1.01. Entry into a material definitive agreement
(June 13, 2006) MEDISCIENCE TECHNOLOGY CORP. (MDSC-OTC) and a New York
Investment Group executed an agreement seeking a minimum of $5 million and a
maximum of $10,000,000 on terms favorable to registrant's shareholders and
providing for a "firm commitment public offering' by Registrants wholly owned
subsidiary for its Ingestible Diagnostic Pill presently under joint development
with its equity partner INFOTONICS Research of Rochester NY --the" Compact
Photonic Explorer". The Underwriting Agreement and related agreements shall
contain such other terms and conditions as are customarily contained in
agreements of such character.

(Submitted in full compliance with sections 8-K 1.01 and 2.01 re: "materiality"
as applicable and in fulfillment of SEC Section 6, 6.01 Regulation (FD) Full
Disclosure, and Section 7 and 7.0 as well as all applicable and presently
effective Sarbanes-Oxley disclosure requirements under Regulation G.


Item 9.01 Financial Statements and Exhibits

      c) Exhibits

99.1      Press Release of the Company, dated June 13, 2006
- --------
MEDISCIENCE TECHNOLOGY CORP. (OTCBB- MDSC) reports Investment Banking Agreement
for a "firm commitment public offering' minimum of $5 million and a maximum of
$10,000,000 for its Ingestible Diagnostic Pill.



                                   SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized on November 12,2004



s/s Peter Katevatis CEO
Mediscience Technology Corp.
June 13, 2006

EX-99.1

                                    EXHIBITS
 99.1   press release

(BW)(NJ-MEDISCIENCE)(MDSC) Mediscience Technology Corp. Reports Investment
Banking Agreement for a "Firm Commitment Public Offering' Minimum of $5 Million
and a Maximum of $10,000,000 for Its Ingestible Diagnostic Pill


CHERRY HILL, N.J.--(BUSINESS WIRE)--June 12, 2006--Mediscience Technology Corp.
(OTCBB: MDSC) and a New York Investment Group executed an agreement seeking a
minimum of $5 million and a maximum of $10,000,000 on terms favorable to the
company's shareholders and providing for a "firm commitment public offering" by
the company's wholly owned subsidiary for its Ingestible Diagnostic Pill (the"
Compact Photonic Explorer") presently under joint development with its equity
partner Info tonics Research of Rochester, NY. The Underwriting Agreement and
related agreements shall contain such other terms and conditions as are
customarily contained in agreements of such character.

Peter Katevatis CEO states that the Mediscience/Infotonics photonic technology
based Biopsy Pill (CPE) application demonstrates great promise in providing a
non-invasive, preliminary means of detecting in vivo pre-cancerous and cancerous
tissues in the upper digestive tract with the use of diagnostic photonics
molecular data as compared to other scientific technology platforms upon which
pill technology is being produced; e.g. (Given Imaging--Olympus). The agreement,
for this IP application , with equity partner Infotonics brings synergistic and
strategic fit leveraging the Center's nano-technology capabilities and resources
to provide Mediscience, present and future associates with an exceptional state
of the art competitive advantage. The Mediscience/Infotonics Photonic Biopsy
Pill has the potential to become a market leader in diagnostic technology,
perhaps the industry standard, as a new molecular diagnostic device that
physicians will embrace because it addresses real concerns of the current
marketplace.

Infotonics Technology Center and Mediscience Technology Corp. (MTC) are jointly
developing the "Compact Photonic Explorer" (CPE), or" pill camera," for medical
applications. The initial focus of the project is developing a (CPE) that would
detect cancer and monitor body functions. The (CPE) stems from a collaborative,
Infotonics-funded research effort at eight universities over the past two years.
The proof-of-concept research for the (CPE) was led by Dr. Robert Alfano and his
team at City University of New York (CUNY), Binghamton, RPI, Rochester Institute
of Technology, the University of Rochester, and Boston University.

                          About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics
Development Company LLC, is engaged in the design, development and
commercialization of medical devices that detect cancer and molecular
physiological change using frequencies of light that are emitted, scattered and
absorbed to distinguish malignant, precancerous, or benign tissues from normal
tissues. Mediscience's exclusive protected non-invasive technology to be
presented to the market place in a broad array of individual applications, one
of which is the (CPE), combines the advantages of real-time results with
enhanced diagnostic sensitivity and specificity compared with other methods of
cancer detection

                           About the Infotonics Center

The Infotonics Technology Center Inc. is a not-for-profit corporation that
operates New York State's Center of Excellence in Photonics and Microsystems.
The Rochester Regional Photonics Clusters an industrial partner, and academic
participants include 20 New York State colleges and universities. Infotonics'
goal is to establish a unique, world-class research and development facility to
enable rapid commercialization of new products. This initiative will provide
major benefits to the region, including creation of jobs and attraction of new
companies and investment revenue.


8-K filing May 24, 2006 52 Pg Syracuse University Report

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp

www.cunyphotonics.com



MEDISCIENCETECH.com

See Mediscience 8-K filing dated September 8, 2004

(See CITIGROUP/Smith Barney Analyst Report 10-1-2004 by Peter Bye. Page 20
Registrant-Infotonics).

                                INVESTOR NOTICE:

Certain of the matters discussed in this announcement contain forward-looking
statements that involve material risks to and uncertainties in the parties/
company's business that may cause actual results to differ materially from those
anticipated by the statements made herein. Such risks and uncertainties include
among other things, the availability of financing, the parties/ company's
ability to implement its long-range business plan for various applications of
its technology; the company's ability to enter into agreements with any
necessary marketing and/or distribution partners; the impact of competition, the
obtaining and maintenance of any necessary US regulatory clearances applicable
to applications of the company' technology; and management of growth and other
risked and uncertainties that may be detailed from time to time in the
parties/company's reports filed with the Securities and Exchange Commission.

This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation,
disclosure and Section 7 and 7.0 as well as all applicable and presently
effective Sarbanes-Oxley disclosure requirements under Regulation G.

                                    CONTACT:
Mediscience Technology Corp:  CEO Peter Katevatis, 215-485-0362 metpk@aol.com
Infotonics Research President David R. Smith, 585-230-5171
david.r.smith@infotonics.org